Inhibrx Biosciences, Inc.
ozekibart
unresectable or metastatic conventional chondrosarcoma
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on ozekibart for unresectable or metastatic conventional chondrosarcoma is expected Date TBD.
Primary source
· SEC 8-K
verified 12h ago
“We plan to submit the Biologics License Application (“BLA”) for ozekibart for the treatment of unresectable or metastatic conventional chondrosarcoma to the U.S. Food and Drug Administration (“FDA”) early in the second quarter of 2026;”